Flagship Pioneering led a $126m Series C round in Omega Therapeutics, a development-stage biotechnology company, with participation from Invus, Fidelity Management & Research Company, BlackRock, Cowen, Point72, Logos Capital and Mirae Asset Capital. "We are grateful to our new and existing investors for the commitment to our bold vision of creating the industry's first fully programmable epigenetic medicines," Mahesh Karande, Omega Therapeutics President and CEO.